The airway pathophysiology of COPD: Implications for treatment

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 2, Issue 2, 2005, Pages 253-262

  Rodríguez Roisin, Roberto ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Airway and systemic inflammation; Fixed combination; Inhaled glucocorticoids; Long acting bronchodilators; Obstructive airway diseases

Indexed keywords

AMINOPHYLLINE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; OXITROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE;

AIRWAY; ANTIINFLAMMATORY ACTIVITY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY MOTILITY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 22244468659     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1081/COPD-57598     Document Type: Review

References (100)

1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349:1498-1504.
2. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J 2002; 20:799-805.
3. Snider GL. Defining chronic obstructive pulmonary disease. In: Calverley P, Pride N, eds. Chronic Obstructive Pulmonary Disease. London: Chapman and Hall, 1995.
4. GOLD. Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2004. National Institutes of Health. National Heart, Lung and Blood Institute: 2004 (www.goldcopd.com).
5. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59(7):574-580.
6. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996; 153(6 pt 1):1802-1811.
7. Vestbo J, Hansen EF. Airway hyperresponsiveness and COPD mortality. Thorax 2001; 56(suppl 2):ii11-ii14.
8. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356(9238):1313-1317.
9. Hogg JC, Wright JL, Wiggs BR, Coxson HO, Opazo Saez A, Pare PD. Lung structure and function in cigarette smokers. Thorax 1994; 49(5):473-478.
10. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530-1535.
11. Melton L. Does muscus hypersecretion matter in airway disease? Lancet 2002; 359:1924.
12. Rogers DF. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis 2000; 55(4):324-332.
13. Smaldone GC, Foster WM, O'Riordan TG, Messina MS, Perry RJ, Langenback EG. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993; 103(5):1390-1396.
14. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest 2000; 117(5 suppl 1):286S-291S.
15. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(9):1618-1623.
16. Fournier M, Lebargy F, Le Roy Ladurie F, Lenormand E, Pariente R. Intraepithelial T-lymphocyte subsets in the airways of normal subjects and of patients with chronic bronchitis. Am Rev Respir Dis 1989; 140(3):737-742.
17. Saetta M, Turato G, Facchini FM, Corbino L, Lucchini RE, Casoni G, Maestrelli P, Mapp CE, Ciaccia A, Fabbri LM. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156(5):1633-1639.
18. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koeter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55(1):12-18.
19. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(26):2645-2653.
20. Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax 2002; 57(8):709-714.
21. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153(2):530-534.
22. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150(6 pt 1):1646-1652.
23. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107(11):1514-1519.
24. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167(8):1090-1095.
25. Rahman I, MacNee W. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax 1996; 51(4):348-350.
26. Gari PG, Busquets X, Morla M, Sauleda J, Agusti A. Upregulation of the inducible form of the nitric oxide synthase and nitrotyrosine formation in skeletal muscle of COPD patients. Eur Respir J 2002; 20:S38.
27. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162(3 pt 1):1175-1177.
28. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429(1-3):195-207.
29. Vogelmeier C, Biedermann T, Maier K, Mazur G, Behr J, Krombach F, Buhl R. Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha 1-protease inhibitor caused by different forms of oxidative stress. Eur Respir J 1997; 10(9):2114-2119.
30. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160(3):893-898.
31. Rogers DF. Mucus hypersecretion in chronic obstructive pulmonary disease. Novartis Found Symp 2001; 234:65-77; discussion 77-83.
32. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley lecture. Chest 2000; 117(5 suppl 1):251S-260S.
33. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(3 pt 1):822-826.
34. Lang MR, Fiaux GW, Gillooly M, Stewart JA, Hulmes DJ, Lamb D. Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax 1994; 49(4):319-326.
35. Sahebjami H, Doers JT, Render ML, Bond TL. Anthropometric and pulmonary function test profiles of outpatients with stable chronic obstructive pulmonary disease. Am J Med 1993; 94(5):469-474.
36. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158(2):629-634.
37. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153(6 pt 1):1958-1964.
38. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996; 153(2):633-637.
39. Maltais F, LeBlanc P, Jobin J, Casaburi R. Peripheral muscle dysfunction in chronic obstructive pulmonary disease. Clin Chest Med 2000; 21(4):665-677.
40. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-946.
41. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93(3):391-398.
42. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1(8222):681-686.
43. Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002 (4):CD001495.
44. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995; 8(9):1506-1513.
45. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161(4 pt 1):1136-1142.
46. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2):217-224.
47. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2):209-216.
48. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115(4):957-965.
49. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155(4):1283-1289.
50. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19(5):936-943.
51. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66(5):434-439.
52. Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 2001; 120(1):258-270.
53. Chambers C, Corrigan B, Newhouse M. Salmeterol (S) speeds mucociliary transport (MCT) in healthy subjects. Am J Respir Crit Care Med 1999; 159:A636.
54. Melloni B, Germouty J. The influence of a new beta agonist: formoterol on mucociliary function. Rev Mal Respir 1992; 9(5):503-507.
55. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11(1):86-90.
56. Bloemen PG, van den Tweel MC, Henricks PA, Engels F, Kester MH, van de Loo PG, Blomjous FJ, Nijkamp FP. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 1997; 272(4 Pt 1):L580-L587.
57. Pennings HJ, Dentener MA, Buurman WA, Wouters EFM. Salbutamol and salmeterol modulate cytokine production by peripheral blood monocytes. Eur Respir J 1995; 8(suppl 19):1871.
58. 2-agonists: a comparison of salbutamol and salmterol. Eur Respir J 1995; 8(suppl 19):2692.
59. Oddera S, Silvestri M, Scarso L, Testi R, Rossi GA. Salmeterol inhibits the allergen-induced mononuclear cell proliferation and downregulates GM-CSF release and HLA-DR expression by monocytes. Pulm Pharmacol Ther 1997; 10(1):43-49.
60. Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E, Hutter D, Turini P, Hugli O, Cook S, Nicod P, Scherrer U. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002; 346(21):1631-1636.
61. Harris T, Koutsoubos V, Guida E. Salmeterol modulates cell proliferation on thrombin stimulated human cultured airway smooth muscle via an action independent of the beta2-adrenoceptor. Am J Respir Crit Care Med 1999; 159:A530.
62. Mio T, Adachi Y, Carnevali S, Romberger D, Spurzem J, Rennard S. Beta-adrenergic agonists attenuate fibroblast-mediated contraction of released collagen gels. Am J Physiol 1996; 70:L829-L835.
63. Hawes HG, Yokoba M, Katagiri M, Abe T, Johnson M, Easton PA. Inhaled salmeterol increases parasternal EMG activity. Eur Respir J 2003; 22(suppl 45):469s.
64. Culpitt SV, De Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165(10):1371-1376.
65. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167(6):813-818.
66. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002; 99(13):8921-8926.
67. Aubier M, De Troyer A, Sampson M, Macklem PT, Roussos C. Aminophylline improves diaphragmatic contractility. N Engl J Med 1981; 305(5):249-252.
68. Yildiz F, Kaur AC, Ilgazli A, Celikoglu M, Kacar Ozkara S, Paksoy N, Ozkarakas O. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000; 67(1):71-76.
69. Balbi B, Majori M, Bertacco S, Convertino G, Cuomo A, Donner CF, Pesci A. Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest 2000; 117(6):1633-1637.
70. Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghe B, Spanevello A. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53(7):583-585.
71. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153(2):616-621.
72. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165(12):1592-1596.
73. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002; 57(9):799-803.
74. Verhoeven GT, Hegmans JPJJ, Mulder PGH, Hoogsteden HC, Prins JB. Effect of an inhaled glucocorticosteroid, fluticasone propionate (FP) on inflammation in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). Am J Respir Crit Care Med 1999; 159:A524.
75. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320(7245):1297-1303.
76. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356):449-456.
77. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(1):74-81.
78. Weiner P, Weiner M, Rabner M, Waizman J, Magadle R, Zamir D. The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. J Intern Med 1999; 245(1):83-89.
79. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(4):580-584.
80. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20(4):819-825.
81. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2(1):67-74.
82. Suissa S. Effectiveness of inhaled corticosteroids in COPD: immortal time bias in observational studies. Am J Respir Crit Care Med 2003.
83. Sin DD, Man SFP, Tu JV. Inhaled glucocorticosteroids in COPD: immortal time bias. Letter to editor. Am J Respir Crit Care Med 2003; 168:126.
84. Pride NB, Vestbo J, Soriano JB, Kiri V. Inhaled glucocorticosteroids in COPD: immortal time bias. Letter to editor. Am J Respir Crit Care Med 2003; 168:127.
85. Fan VS, Bryson CL, Curtis JR, Fihn SD, Bridevaux PO, McDonell MB, Au DH. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003; 168(12):1488-1494.
86. Kumar SD, Brieva JL, Danta I, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med 2000; 161(3 pt 1):918-921.
87. Horvath G, Lieb T, Conner GE, Salathe M, Wanner A. Steroid sensitivity of norepinephrine uptake by human bronchial arterial and rabbit aortic smooth muscle cells. Am J Respir Cell Mol Biol 2001; 25(4):500-506.
88. Acuña AA, Gabrijelcic J, Uribe EM, Rabinovich R, Roca J, Barbera JA, Chung KF, Rodriguez-Roisin R. Fluticasone propionate attenuates platelet-activating factor-induced gas exchange defects in mild asthma. Eur Respir J 2002; 19(5):872-878.
89. Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 2003; 21(6):989-993.
90. Hanania NA, Darken P, Horstman D, Reisner MD, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate 250 mcg/salmeterol 50 mcg combined in the discus inhaler for the treatment of chronic obstructive pulmonary disease. Chest 2003; 124:834-843.
91. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8):1084-1091.
92. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6):912-919.
93. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105(5):1411-1419.
94. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65(5):354-362.
95. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15(5):878-885.
96. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297(1):267-279.
97. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ. SB 207499 (ariflo) a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998; 287(2):705-711.
98. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168(8):976-982.
99. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358(9278):265-270.
100. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 2002; 57(1):48-64.